6Suppliers
18Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Tonix Pharmaceuticals Holding Corp. (TNXP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

28Total relationships
4Distinct source URLs
10High confidence
0.778Average confidence
2026-10-29Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Tonix Pharmaceuticals Holding Corp. Suppliers

TickerNameConfidenceEvidence
EVERANA EVERANA 90% In 2024, Tonix engaged EVERSANA to support the launch strategy and commercial planning of TONMYA for the treatment of fibromyalgia.
AXSM Axsome Therapeutics, Inc. 72% Reciprocal relationship from AXSM graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from AXSM graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from AXSM g…
AZN AstraZeneca PLC 72% Reciprocal relationship from AZN graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from AZN graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from AZN grap…
DFTX Definium Therapeutics, Inc. 72% Reciprocal relationship from DFTX graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from DFTX graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from DFTX g…
DWTX Dogwood Therapeutics, Inc. 72% Reciprocal relationship from DWTX graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from DWTX graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from DWTX g…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from JNJ grap…

Tonix Pharmaceuticals Holding Corp. Customers

TickerNameConfidenceEvidence
GROUP-PURCHASING-ORGANIZATION GROUP-PURCHASING-ORGANIZATION 92% On May 6, 2026, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced it entered into an agreement with a group purchasing organization (“GPO”) that provides coverage for TONMYA ® .
CUSTOMERS CUSTOMERS 90% For the three months ended March 31, 2026, revenues from three customers accounted for 30 %, 28 % and 18 % of net product revenues, respectively.
SPECIALTY-PHARMACIES SPECIALTY-PHARMACIES 90% Tonix has contracted with its existing wholesalers and specialty pharmacies for the distribution of TONMYA.
NATIONAL-PHARMACEUTICAL-WHOLESALERS NATIONAL-PHARMACEUTICAL-WHOLESALERS 85% TONMYA is distributed in the United States through national pharmaceutical wholesalers and specialty distributors pursuant to customary commercial arrangements.
SPECIALTY-DISTRIBUTORS SPECIALTY-DISTRIBUTORS 85% TONMYA is distributed in the United States through national pharmaceutical wholesalers and specialty distributors pursuant to customary commercial arrangements.
AXSM Axsome Therapeutics, Inc. 72% Reciprocal relationship from AXSM graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from AXSM graph: Reciprocal relationship from TNXP graph: arket strategy. Our commercializati…
AXSM Axsome Therapeutics, Inc. 72% arket strategy. Our commercialization strategy for TONMYA is centered on a cost-efficient, targeted sales and marketing approach focused on the top prescribing healthcare providers who treat patients…
AZN AstraZeneca PLC 72% Reciprocal relationship from AZN graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from AZN graph: Reciprocal relationship from TNXP graph: arket strategy. Our commercialization…
AZN AstraZeneca PLC 72% arket strategy. Our commercialization strategy for TONMYA is centered on a cost-efficient, targeted sales and marketing approach focused on the top prescribing healthcare providers who treat patients…
BNTX BioNTech SE 72% Reciprocal relationship from BNTX graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from BNTX g…
BNTX BioNTech SE 72% arket strategy. Our commercialization strategy for TONMYA is centered on a cost-efficient, targeted sales and marketing approach focused on the top prescribing healthcare providers who treat patients…
DFTX Definium Therapeutics, Inc. 72% arket strategy. Our commercialization strategy for TONMYA is centered on a cost-efficient, targeted sales and marketing approach focused on the top prescribing healthcare providers who treat patients…
DFTX Definium Therapeutics, Inc. 72% Reciprocal relationship from DFTX graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from DFTX graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from DFTX g…
DWTX Dogwood Therapeutics, Inc. 72% Reciprocal relationship from DWTX graph: Reciprocal relationship from TNXP graph: arket strategy. Our commercialization strategy for TONMYA is centered on a cost-efficient, targeted sales and marketi…
DWTX Dogwood Therapeutics, Inc. 72% arket strategy. Our commercialization strategy for TONMYA is centered on a cost-efficient, targeted sales and marketing approach focused on the top prescribing healthcare providers who treat patients…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from TNXP graph: arket strategy. Our commercialization strategy for TONMYA is centered on a cost-efficient, targeted sales and marketin…
JNJ Johnson & Johnson 72% arket strategy. Our commercialization strategy for TONMYA is centered on a cost-efficient, targeted sales and marketing approach focused on the top prescribing healthcare providers who treat patients…
UPSHER-SMITH-LABORATORIES-LLC UPSHER-SMITH-LABORATORIES-LLC 62% expected to affect future collections experience. Any allowance would reduce the net receivables to the amount that is expected to be collected. The payment history of the Company’s customers will be…

Tonix Pharmaceuticals Holding Corp. Debt Obligations

InstrumentDescriptionConfidenceEvidence
TNXP-DEBT-13045 Warrants outstanding: 4.25 90% xbrl warrant detail from xbrl 2024-12-31.
TNXP-DEBT Debt stack $7.5M 90% Market cache reports total debt of $7.5M.
TNXP-DEBT-13046 Xbrl Convertible 90% xbrl convertible detail from xbrl 2013-12-31.

Tonix Pharmaceuticals Holding Corp. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Tonix Pharmaceuticals Holding Corp..

Tonix Pharmaceuticals Holding Corp. Ownership

HolderNameConfidenceEvidence
TNXP-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC VANGUARD CAPITAL MANAGEMENT LLC 90% 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 82 tracked holders.

Tonix Pharmaceuticals Holding Corp. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CCCC C4 Therapeutics, Inc. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
BNRG Brenmiller Energy Ltd 100.00 2
ANIK Anika Therapeutics, Inc. 100.00 2
BLLN BillionToOne, Inc. 100.00 2
CSTE Caesarstone Ltd. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
BNR Burning Rock Biotech Limited 100.00 2
AVBP ArriVent BioPharma, Inc. 100.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 100.00 2
DEO Diageo plc 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
AZN AstraZeneca PLC 100.00 1 ['customer', 'supplier']
DWTX Dogwood Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
DFTX Definium Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
AXSM Axsome Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
AORT Artivion, Inc. 100.00 2
AUTL Autolus Therapeutics plc 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
SNNUF Smith & Nephew plc 100.00 2
🔐
TNXP
Unlock TNXP Supply Chain Data
Verified relationships include:
EVERANAEVERANASupplier90%
AXSMAxsome Therapeutics, Inc.Supplier72%
GROUP-PURCHASING-ORGANIZATIONGROUP-PURCHASING-ORGANIZATIONCustomer92%
CUSTOMERSCUSTOMERSCustomer90%
+24 more relationships locked
Subscribe, View plans →